SLT recommended as first line therapy

The Global RDH12 Alliance unites inherited retinal disease advocacy groups including UK-based Eyes on the Future and the US-based RDH12 Fund for Sight

Exonate initiates a phase 2b trial for EXN407, a groundbreaking eye drop treatment for diabetic retinopathy

The companies will focus their joint effort on extended-release therapies for ocular disease

Optical coherence tomography may help identify patients at risk of cardiovascular disease before coronary angiography

According to the company, the EMA’s opinion was based on the “totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package”